CA2804753C - Anti-angiogenic cd2 derived polypeptide for treating angiogenesis-dependent disorder - Google Patents
Anti-angiogenic cd2 derived polypeptide for treating angiogenesis-dependent disorder Download PDFInfo
- Publication number
- CA2804753C CA2804753C CA2804753A CA2804753A CA2804753C CA 2804753 C CA2804753 C CA 2804753C CA 2804753 A CA2804753 A CA 2804753A CA 2804753 A CA2804753 A CA 2804753A CA 2804753 C CA2804753 C CA 2804753C
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- angiogenic
- variant
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36393310P | 2010-07-13 | 2010-07-13 | |
| US61/363,933 | 2010-07-13 | ||
| PCT/US2011/043907 WO2012009471A1 (en) | 2010-07-13 | 2011-07-13 | Anti-angiogenic agent and method of using such agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2804753A1 CA2804753A1 (en) | 2012-01-19 |
| CA2804753C true CA2804753C (en) | 2021-05-25 |
Family
ID=44629339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2804753A Active CA2804753C (en) | 2010-07-13 | 2011-07-13 | Anti-angiogenic cd2 derived polypeptide for treating angiogenesis-dependent disorder |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9175063B2 (enExample) |
| EP (2) | EP3381462B1 (enExample) |
| JP (2) | JP6353654B2 (enExample) |
| CN (1) | CN103002904B (enExample) |
| AU (5) | AU2011279155B2 (enExample) |
| CA (1) | CA2804753C (enExample) |
| DK (1) | DK2593127T3 (enExample) |
| ES (2) | ES2923430T3 (enExample) |
| HU (1) | HUE040205T2 (enExample) |
| PL (1) | PL2593127T3 (enExample) |
| PT (2) | PT3381462T (enExample) |
| WO (1) | WO2012009471A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2593127T3 (en) * | 2010-07-13 | 2018-07-02 | Georgia State Univ Research Foundation | ANTIANGIOGENTIC AGENT AND METHOD OF USING SUCH AGENTS |
| EP4706760A3 (en) * | 2015-03-06 | 2026-05-27 | Georgia State University Research Foundation, Inc. | Integrin-targeting protein and methods of use thereof |
| CN110317264B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 一种抗肿瘤蛋白内皮抑素的衍生物 |
| CN108148117A (zh) * | 2017-12-26 | 2018-06-12 | 张艳雪 | 一种抗菌肽的蛋白质结构特性及其研究方法 |
| EP4665378A2 (en) * | 2023-02-14 | 2025-12-24 | Georgia State University Research Foundation, Inc. | Anti-angiogenic agent and methods of using such agent |
| WO2025250689A1 (en) * | 2024-05-28 | 2025-12-04 | Georgia State University Research Foundation | Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990008187A1 (en) * | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
| US6162432A (en) * | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| JP4596916B2 (ja) * | 2002-09-05 | 2010-12-15 | メディミューン，エルエルシー | Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法 |
| EP1718329A4 (en) * | 2004-02-06 | 2008-09-10 | Astellas Us Llc | Methods of treating skin disorders |
| JP5377965B2 (ja) * | 2005-09-09 | 2013-12-25 | ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド | 標的化された造影剤および造影剤を標的化するための方法 |
| WO2009146099A2 (en) * | 2008-04-02 | 2009-12-03 | Georgia State University Research Foundation, Inc. | Contrast agents, methods for preparing contrast agents, and methods of imaging |
| EP2599497A3 (en) * | 2008-09-08 | 2013-09-25 | Hoffman/Barrett, L.L.C. | Porphyrazine-chemotherapeutic agents conjugates |
| DK2593127T3 (en) * | 2010-07-13 | 2018-07-02 | Georgia State Univ Research Foundation | ANTIANGIOGENTIC AGENT AND METHOD OF USING SUCH AGENTS |
-
2011
- 2011-07-13 DK DK11738546.8T patent/DK2593127T3/en active
- 2011-07-13 PT PT181685983T patent/PT3381462T/pt unknown
- 2011-07-13 PL PL11738546T patent/PL2593127T3/pl unknown
- 2011-07-13 ES ES18168598T patent/ES2923430T3/es active Active
- 2011-07-13 WO PCT/US2011/043907 patent/WO2012009471A1/en not_active Ceased
- 2011-07-13 JP JP2013519804A patent/JP6353654B2/ja active Active
- 2011-07-13 PT PT117385468T patent/PT2593127T/pt unknown
- 2011-07-13 EP EP18168598.3A patent/EP3381462B1/en active Active
- 2011-07-13 CN CN201180034591.9A patent/CN103002904B/zh active Active
- 2011-07-13 EP EP11738546.8A patent/EP2593127B1/en active Active
- 2011-07-13 ES ES11738546.8T patent/ES2674409T3/es active Active
- 2011-07-13 CA CA2804753A patent/CA2804753C/en active Active
- 2011-07-13 AU AU2011279155A patent/AU2011279155B2/en active Active
- 2011-07-13 HU HUE11738546A patent/HUE040205T2/hu unknown
- 2011-07-13 US US13/739,241 patent/US9175063B2/en active Active
-
2015
- 2015-10-30 US US14/928,890 patent/US11578114B2/en active Active
-
2016
- 2016-04-11 JP JP2016078990A patent/JP2016175913A/ja active Pending
-
2017
- 2017-02-20 AU AU2017201133A patent/AU2017201133A1/en not_active Abandoned
-
2019
- 2019-03-29 AU AU2019202174A patent/AU2019202174B2/en active Active
-
2021
- 2021-02-24 AU AU2021201207A patent/AU2021201207A1/en not_active Abandoned
-
2023
- 2023-04-26 AU AU2023202513A patent/AU2023202513A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016175913A (ja) | 2016-10-06 |
| AU2019202174A1 (en) | 2019-04-18 |
| EP2593127B1 (en) | 2018-05-30 |
| ES2674409T3 (es) | 2018-06-29 |
| PL2593127T3 (pl) | 2018-11-30 |
| DK2593127T3 (en) | 2018-07-02 |
| AU2023202513A1 (en) | 2023-05-11 |
| AU2011279155A1 (en) | 2013-01-24 |
| AU2011279155B2 (en) | 2017-03-09 |
| HUE040205T2 (hu) | 2019-02-28 |
| ES2923430T3 (es) | 2022-09-27 |
| CA2804753A1 (en) | 2012-01-19 |
| AU2017201133A1 (en) | 2017-03-09 |
| AU2019202174B2 (en) | 2020-11-26 |
| US11578114B2 (en) | 2023-02-14 |
| PT2593127T (pt) | 2018-07-06 |
| EP3381462B1 (en) | 2022-06-08 |
| JP2013534538A (ja) | 2013-09-05 |
| CN103002904A (zh) | 2013-03-27 |
| WO2012009471A1 (en) | 2012-01-19 |
| JP6353654B2 (ja) | 2018-07-04 |
| CN103002904B (zh) | 2017-01-18 |
| US9175063B2 (en) | 2015-11-03 |
| US20160090408A1 (en) | 2016-03-31 |
| PT3381462T (pt) | 2022-07-22 |
| EP3381462A1 (en) | 2018-10-03 |
| AU2021201207A1 (en) | 2021-03-11 |
| US20130281357A1 (en) | 2013-10-24 |
| EP2593127A1 (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019202174B2 (en) | Anti-angiogenic agent and method of using such agent | |
| US20210008173A1 (en) | Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury | |
| US12410230B2 (en) | Anti-angiogenic agent and methods of using such agent | |
| US20100203048A1 (en) | Methods of using corticotropin-releasing factor for the use of the treatment of cancer | |
| EP4665378A2 (en) | Anti-angiogenic agent and methods of using such agent | |
| US20120183536A1 (en) | Methods of using corticotropin-releasing factor for the treatment of cancer | |
| US20240390465A1 (en) | Endostatin Peptides for the Treatment of Tumors, Fibrosis and Acute Lung Injury | |
| US20240158521A1 (en) | DNA-ENCODED BISPECIFIC ANTIBODIES TARGETING IL13Ra2 AND METHODS OF USE IN CANCER THERAPEUTICS | |
| US20230241167A1 (en) | Use of Caveolin-1 Scaffolding Domain Peptides for Treating Disease and Disorders | |
| WO2010057962A2 (en) | Crf conjugates with extended half-lives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130108 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD Year of fee payment: 14 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250707 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250707 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260706 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260706 |